The patent, titled Systems and Methods for Treating Cancer and/or Augmenting Organ Function, covers the company technology, including systems, methods, and devices for interventionally treating cancerous tumors and cancer-related pain. Autonomix plans to use the technology for pancreatic cancer-related pain.

“As we continue to advance the development of this potentially groundbreaking technology, bolstering our patent protection remains a key priority,” CEO Brad Hauser said in a news release. “Supported by recent positive preclinical results demonstrated to date, we believe the depth and breadth of our proprietary technology provides the opportunity for further evaluation and we intend to explore its potential to reduce cancer progression and metastases.”

Autonomix reported positive results from a preclinical study in mice that demonstrated its targeted nerve ablation technology significantly reduced metastases and tumor mass in pancreatic cancer models. The company said the findings suggest that neural pathways play a critical role in the development of pancreatic cancer.